JP2018533625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533625A5 JP2018533625A5 JP2018543036A JP2018543036A JP2018533625A5 JP 2018533625 A5 JP2018533625 A5 JP 2018533625A5 JP 2018543036 A JP2018543036 A JP 2018543036A JP 2018543036 A JP2018543036 A JP 2018543036A JP 2018533625 A5 JP2018533625 A5 JP 2018533625A5
- Authority
- JP
- Japan
- Prior art keywords
- hspc
- cancer
- seq
- cells
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 25
- 108091033409 CRISPR Proteins 0.000 claims description 21
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 21
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 238000010354 CRISPR gene editing Methods 0.000 claims description 19
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 210000001165 lymph node Anatomy 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims 11
- 230000037430 deletion Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 238000003780 insertion Methods 0.000 claims 10
- 230000037431 insertion Effects 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 3
- 229930024421 Adenine Natural products 0.000 claims 3
- 229960000643 adenine Drugs 0.000 claims 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 4
- 208000001640 Fibromyalgia Diseases 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
- 238000011357 CAR T-cell therapy Methods 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 201000002829 CREST Syndrome Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021065361A JP7378439B2 (ja) | 2015-11-04 | 2021-04-07 | 造血幹細胞における遺伝子編集のための方法および組成物 |
| JP2023097365A JP2023115069A (ja) | 2015-11-04 | 2023-06-14 | 造血幹細胞における遺伝子編集のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250561P | 2015-11-04 | 2015-11-04 | |
| US62/250,561 | 2015-11-04 | ||
| PCT/US2016/060273 WO2017079400A1 (en) | 2015-11-04 | 2016-11-03 | Methods and compositions for gene editing in hematopoietic stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021065361A Division JP7378439B2 (ja) | 2015-11-04 | 2021-04-07 | 造血幹細胞における遺伝子編集のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533625A JP2018533625A (ja) | 2018-11-15 |
| JP2018533625A5 true JP2018533625A5 (enExample) | 2019-12-05 |
| JP6866385B2 JP6866385B2 (ja) | 2021-04-28 |
Family
ID=58662736
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543036A Active JP6866385B2 (ja) | 2015-11-04 | 2016-11-03 | 造血幹細胞における遺伝子編集のための方法および組成物 |
| JP2021065361A Active JP7378439B2 (ja) | 2015-11-04 | 2021-04-07 | 造血幹細胞における遺伝子編集のための方法および組成物 |
| JP2023097365A Pending JP2023115069A (ja) | 2015-11-04 | 2023-06-14 | 造血幹細胞における遺伝子編集のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021065361A Active JP7378439B2 (ja) | 2015-11-04 | 2021-04-07 | 造血幹細胞における遺伝子編集のための方法および組成物 |
| JP2023097365A Pending JP2023115069A (ja) | 2015-11-04 | 2023-06-14 | 造血幹細胞における遺伝子編集のための方法および組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10548922B2 (enExample) |
| EP (1) | EP3370741B1 (enExample) |
| JP (3) | JP6866385B2 (enExample) |
| KR (1) | KR20180073679A (enExample) |
| CN (1) | CN108463227A (enExample) |
| AU (2) | AU2016349280B2 (enExample) |
| BR (1) | BR112018009098A8 (enExample) |
| CA (1) | CA3004053A1 (enExample) |
| CL (1) | CL2018001198A1 (enExample) |
| EA (1) | EA201891092A1 (enExample) |
| HK (1) | HK1259151A1 (enExample) |
| IL (1) | IL259084A (enExample) |
| MX (1) | MX2018005612A (enExample) |
| MY (1) | MY185961A (enExample) |
| PH (1) | PH12018500965A1 (enExample) |
| SG (2) | SG10202107602XA (enExample) |
| WO (1) | WO2017079400A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3025719B1 (en) | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| EP4265633A3 (en) | 2015-10-16 | 2024-01-24 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| EA201891092A1 (ru) * | 2015-11-04 | 2018-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках |
| WO2017143266A1 (en) * | 2016-02-19 | 2017-08-24 | The Regents Of The University Of California | Short hairpin rna (shrna734) and use of same to positively select and eliminate genetically modified cells |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| SG11201903454VA (en) * | 2016-11-02 | 2019-05-30 | Univ Basel | Immunologically discernible cell surface variants for use in cell therapy |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018160768A1 (en) | 2017-02-28 | 2018-09-07 | Vor Biopharma, Inc. | Compositions and methods for inhibition lineage specific proteins |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3794130A4 (en) | 2018-05-16 | 2022-07-27 | Synthego Corporation | METHODS AND SYSTEMS FOR DESIGNING AND USING GUIDE RNA |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| IL260445B (en) * | 2018-07-05 | 2019-08-29 | Lempo Therapeutics Ltd | Methods and compositions for modulating myeloperoxidase (mpo) expression |
| MX2021002415A (es) | 2018-08-28 | 2021-09-21 | Vor Biopharma Inc | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. |
| KR20210061397A (ko) * | 2018-09-19 | 2021-05-27 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 키메라 항원 수용체-변형된 면역 세포의 활성화 및 확장을 위한 단백질 l |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| JP2022513412A (ja) * | 2018-10-31 | 2022-02-07 | ヒューマニゲン インコーポレイティッド | 癌を治療するための物質及び方法 |
| CN109852627B (zh) * | 2018-12-26 | 2022-07-05 | 中国人民解放军军事科学院军事医学研究院 | 用于CRISPRi系统的质粒、其构建方法及其在使鼠疫菌目的基因定向沉默中的应用 |
| AU2020207962A1 (en) * | 2019-01-18 | 2021-07-22 | University Of Southern California | Methods and compositions to improve the safety and efficacy of cellular therapies |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020172638A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of The University Of Pennsylvania | Crispr/cas9 knock-out of cd33 in human hematopoietic stem/ progenitor cells for allogenic transplantation |
| EP3935156A4 (en) * | 2019-03-07 | 2022-12-28 | The Regents of The University of California | CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF |
| DE112020001342T5 (de) | 2019-03-19 | 2022-01-13 | President and Fellows of Harvard College | Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| MX2022002462A (es) * | 2019-08-28 | 2022-06-02 | Vor Biopharma Inc | Composiciones y métodos para la modificación de cll1. |
| CN114787352A (zh) * | 2019-08-28 | 2022-07-22 | Vor生物制药股份有限公司 | 用于cd123修饰的组合物和方法 |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| EP4041297A4 (en) | 2019-10-11 | 2024-02-28 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS FOR TREATING ACUTE MYELOID LEUKEMIA |
| KR20210109971A (ko) | 2020-02-28 | 2021-09-07 | 현대자동차주식회사 | 리튬이온 전지 음극 제조방법 및 이에 의해 제조된 리튬이온 전지 음극을 포함하는 리튬이온 전지 |
| GB2614813B (en) | 2020-05-08 | 2025-05-07 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| JP2024502820A (ja) * | 2020-12-31 | 2024-01-23 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３４遺伝子改変のための組成物及び方法 |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| TW202309283A (zh) * | 2021-04-28 | 2023-03-01 | 日商衛材R&D企管股份有限公司 | 反義寡核苷酸及其用於治療神經變性障礙之用途 |
| WO2023086422A1 (en) * | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| WO2023091954A2 (en) | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy |
| CA3247767A1 (en) * | 2022-01-11 | 2023-07-20 | Actinium Pharmaceuticals Inc | METHODS FOR THE TREATMENT OF CD33 POSITIVE MALIGNANT HEMATIC DISEASE |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025059062A1 (en) * | 2023-09-11 | 2025-03-20 | The Trustees Of The University Of Pennsylvania | Genetic engineering of human hematopoietic stem/progenitor cells (hspcs) for locus-specific expression of therapeutic proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2099911A2 (en) * | 2007-01-11 | 2009-09-16 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| UY35340A (es) * | 2013-02-20 | 2014-09-30 | Novartis Ag | Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123 |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| EP4406610A3 (en) * | 2014-04-07 | 2024-10-30 | Novartis AG | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| EP4265633A3 (en) * | 2015-10-16 | 2024-01-24 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| EA201891092A1 (ru) * | 2015-11-04 | 2018-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках |
-
2016
- 2016-11-03 EA EA201891092A patent/EA201891092A1/ru unknown
- 2016-11-03 SG SG10202107602XA patent/SG10202107602XA/en unknown
- 2016-11-03 WO PCT/US2016/060273 patent/WO2017079400A1/en not_active Ceased
- 2016-11-03 KR KR1020187015530A patent/KR20180073679A/ko not_active Withdrawn
- 2016-11-03 JP JP2018543036A patent/JP6866385B2/ja active Active
- 2016-11-03 CA CA3004053A patent/CA3004053A1/en active Pending
- 2016-11-03 BR BR112018009098A patent/BR112018009098A8/pt not_active Application Discontinuation
- 2016-11-03 AU AU2016349280A patent/AU2016349280B2/en not_active Ceased
- 2016-11-03 HK HK19101177.2A patent/HK1259151A1/zh unknown
- 2016-11-03 MX MX2018005612A patent/MX2018005612A/es unknown
- 2016-11-03 SG SG11201803701YA patent/SG11201803701YA/en unknown
- 2016-11-03 CN CN201680076538.8A patent/CN108463227A/zh active Pending
- 2016-11-03 EP EP16862941.8A patent/EP3370741B1/en active Active
- 2016-11-03 MY MYPI2018701723A patent/MY185961A/en unknown
-
2018
- 2018-05-01 IL IL259084A patent/IL259084A/en unknown
- 2018-05-03 CL CL2018001198A patent/CL2018001198A1/es unknown
- 2018-05-03 US US15/970,605 patent/US10548922B2/en active Active
- 2018-05-04 PH PH12018500965A patent/PH12018500965A1/en unknown
-
2019
- 2019-12-19 US US16/721,156 patent/US11771719B2/en active Active
-
2021
- 2021-04-07 JP JP2021065361A patent/JP7378439B2/ja active Active
-
2023
- 2023-06-14 JP JP2023097365A patent/JP2023115069A/ja active Pending
- 2023-09-14 US US18/467,223 patent/US20240066064A1/en active Pending
-
2024
- 2024-01-01 AU AU2024200000A patent/AU2024200000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533625A5 (enExample) | ||
| Jia et al. | NK cell exhaustion in the tumor microenvironment | |
| JP7273421B2 (ja) | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 | |
| Xue et al. | Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| Chang et al. | Immune reconstitution after haploidentical hematopoietic stem cell transplantation | |
| JP2018500006A5 (enExample) | ||
| JP2017533706A5 (enExample) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| ES2910227T3 (es) | Composición y métodos para la estimulación y expansión de células T | |
| US20110020308A1 (en) | Expression of transgenic t cell receptors in lak-t cells | |
| CN111989118A (zh) | 包含耗竭性抗cd4单克隆抗体的抗癌t细胞治疗剂辅助用组合物及其用途 | |
| Golchin et al. | Promotion of cell-based therapy: special focus on the cooperation of mesenchymal stem cell therapy and gene therapy for clinical trial studies | |
| Zhang et al. | Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth | |
| Garber et al. | Adoptive T-cell therapy for Leukemia | |
| Fisher et al. | T-regulatory cells for the treatment of autoimmune diseases | |
| Mondino et al. | To remember or to forget: the role of good and bad memories in adoptive T cell therapy for tumors | |
| CN112262212B (zh) | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 | |
| Motais et al. | A bird’s-Eye View of Cell sources for cell-based therapies in blood cancers | |
| Zhao et al. | The role of mesenchymal stem cells in cancer immunotherapy | |
| Kravets et al. | Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy | |
| Xu et al. | Profiling pharmacokinetics of double‐negative T cells and cytokines via a single intravenous administration in NSG mice | |
| Fukuta et al. | Cell therapies against brain tumors: Clinical development and emerging prospects | |
| Peng et al. | The progress and perspectives of CAR-T cell therapy | |
| Cao et al. | Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells |